Zydus Wellness Ltd. Share Price

NESTLE, ZYDUS WELLNESS SHARES PLUNGE TO SIX-MONTH LOW

Shares of Nestlé India and Zydus Wellness came under selling pressure after the Food Safety and Standards Authority of India issued notices to both companies over allegedly misleading claims in their product advertisements. The regulator has sought scientific evidence from the companies to substantiate the claims made in their promotional and labelling materials. Nestlé India shares fell around 3.7% to touch a six-month low, while Zydus Wellness declined more than 3%, slipping below its six-month low. At the time of writing, Nestlé India shares were trading down 3%, The stock opened at Rs 1,210 before declining to an intraday low of Rs 1,184. It was also the top loser on the Nifty FMCG index, which was down around 2%. The food safety regulator issued notices to Nestlé India over claims and promotional materials related to its Lactogen Pro 1 Powder and Nan Excella Pro Stage 1 products. It also issued a notice to Zydus Wellness Products Ltd concerning claims made for its Complan nutritional drink. The regulator has asked Nestlé India to provide scientific evidence supporting the claim that whey protein is easy to digest. The company has also been directed to submit the required documents and supporting evidence within the stipulated period and explain why action should not be initiated against it under the Food Safety and Standards Act, 2006. For Zydus Wellness' Complan, FSSAI raised concerns over product labelling featuring images of two children and claims such as “2X Faster Growth”, “Supports Concentration and Memory” and “Pro Immunity+ 34 Vital Nutrients”.

See More

Nestle, Zydus Wellness hit 6 month lows after FSSAI notices

Nestle India and Zydus Wellness came under sharp pressure on Thursday after the Food Safety and Standards Authority of India (FSSAI) issued notices to both companies over allegedly misleading claims on certain ***** India stock fell nearly 3.7 per cent to hit a six-month low of Rs 1,187.10. At the time of writing, it was trading around Rs 1,187, down about 3 per cent. Zydus Wellness dropped over 3 per cent, slipping below its six-month low to around Rs ***** regulator has questioned Nestle’s claims on two infant nutrition products—Lactogen Pro 1 and Nan Excella Pro Stage 1. FSSAI has sought scientific proof for statements such as whey protein being “easy to digest” and “5 HMOs help support the normal immune system.” The regulator has also asked Nestle to explain why action should not be initiated under the FSS ***** the case of Zydus Wellness’ Complan, FSSAI flagged claims including “2X Faster Growth,” “Supports Concentration and Memory,” and “Pro Immunity+ 34 Vital Nutrients,” along with the advertisement line “growth comes in 4 flavors.” The company has been directed to provide scientific justification.

See More

Zydus Wellness: Premium brands drive the growth opportunity

### Zydus Wellness: Premium brands drive the growth opportunity Zydus Wellness Limited (NSE: ZYDUSWELL) owns consumer brands across nutrition, skincare and wellness, including Sugar Free, Complan, Glucon-D and Everyuth. **Why it matters:** Growth depends on brand strength, distribution reach and consumers trading up to higher-value products. Digital channels and premium offerings can support sales, but advertising costs and competition may limit margin gains. **My view:** The key question is whether Zydus Wellness can sustain volume growth alongside better profitability. Price increases can lift revenue, but repeat purchases and wider distribution provide stronger evidence of underlying demand. Investors should also track whether acquisitions and brand investments generate adequate returns. **What I’m watching:** Volume growth, market share, advertising expenditure, operating margins and cash generation over the next two quarters. **Stance:** Brand-led growth offers potential, but consistent volume expansion and returns on investment remain the key tests. **Disclosure:** I am a SEBI Registered Research Analyst. This content is for educational purposes and is not a recommendation to buy or sell any security. **Suggested tags:** Equity Research + Fundamental Views + Stock In News

See More

Zydus Launches Generic Adempas In US Market

LIFESCIENCES: Zydus Lifesciences Ltd. has launched the first generic version of Adempas, or riociguat tablets, in the United States in partnership with MSN Laboratories. The launch marks another addition to the company’s generic pharmaceutical portfolio in the US market and expands its presence in the segment through a partnership-led commercial opportunity. Riociguat is the active pharmaceutical ingredient associated with Adempas, and the launch provides a generic alternative in the US market following the applicable regulatory and commercial processes. The partnership with MSN Laboratories brings together the respective capabilities of the companies for the launch and supply of the product. The US generics market remains an important market for Indian pharmaceutical companies, with product launches providing opportunities to expand portfolios across various therapeutic categories. Actual commercial performance from the product will depend on market demand, pricing, competition, prescription trends, distribution, market share and other factors. The launch is therefore an operational and product-development update for Zydus Lifesciences and should be viewed in the context of the company’s broader US business. Market participants may track subsequent company disclosures for further information regarding product performance, additional launches and developments in the company’s US generics portfolio. This information is shared strictly as a corporate and market update for informational purposes and should not be considered investment advice, research analysis, or a recommendation to buy or sell any security.

See More

Zydus Wellness shares are trading higher today

Zydus Wellness shares are trading higher today on strong volumes, with recent updates including Q2 FY26 results showing a net loss of ₹52.8 crore, a major leadership appointment, and promoter group shareholding changes. The company also reported FY26 revenue growth of 46% and declared a ₹1.20 dividend. 📊 Latest Market Update Stock Movement (Sept 7, 2026): BSE: ₹569.95 (+7.57%) NSE: ₹537.30 (+1.05%) 52-week range: ₹357.55 – ₹610.95 Shares are seeing heavy trading volumes, marking Zydus Wellness as a “volume shocker” today. 🏢 Corporate Announcements Leadership Appointment: On Sept 1, 2026, Kapil Sharma was appointed as Chief Revenue Officer (India & Subcontinent). He brings 28+ years of experience, including senior roles at Procter & Gamble (VP-Gillette India). Promoter Group Share Transfer: On Aug 21, 2026, 27,250 equity shares were transmitted from late Jasodaben Babubhai Patel to Prashant Babubhai Patel. Disclosure made under SEBI Insider Trading Regulations.

See More